

Table S25: Percent of IgG+ B cells or plasmablasts that are GT8++ (without regard to KO binding status) testing between vaccine dose among detectable response participants. Testing was done using the Wilcoxon rank-sum test (two-sided,  $\alpha = 0.05$ ) and p values less than 0.05 are highlighted. Median, minimum, and maximum values are presented by treatment group and time point.

	Sample Type	Sample Sizes	Median (Range)	P Value
<b>20µg vs. 100µg</b>				
Wk3 (V05)	FNA/IgG GC B cells	11 vs. 13	18.1208 [0.9818, 62.2510] vs. 16.5529 [0.5529, 36.2145]	0.4244
Wk4 (V06)	PBMCs/IgG memory B cells	18 vs. 18	0.1264 [0.0528, 0.3482] vs. 0.2076 [0.0771, 0.8912]	0.1108
Wk8 (V07)	PBMCs/IgG memory B cells	18 vs. 17	0.0833 [0.0208, 0.2884] vs. 0.1142 [0.0404, 0.3422]	0.1528
Wk9 (V07A)	Fresh PBMCs/IgD- PBs	17 vs. 17	11.1658 [0.5544, 37.2911] vs. 6.9645 [0.2990, 26.2222]	0.2451
Wk10 (V08)	PBMCs/IgG memory B cells	17 vs. 17	2.0403 [0.3117, 7.6517] vs. 2.7716 [0.9187, 9.1259]	0.1309
Wk11 (V09)	FNA/IgG GC B cells	12 vs. 10	41.0265 [15.7441, 68.1154] vs. 12.6427 [0.5413, 42.6906]	0.0020
Wk16 (V10)	PBMCs/IgG memory B cells	18 vs. 16	0.5411 [0.1139, 1.7309] vs. 0.9596 [0.1715, 3.0402]	0.0504